178 related articles for article (PubMed ID: 23828279)
21. Late relapse in primary central nervous system lymphoma: clonal persistence.
Nayak L; Hedvat C; Rosenblum MK; Abrey LE; DeAngelis LM
Neuro Oncol; 2011 May; 13(5):525-9. PubMed ID: 21372070
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).
Hattori Y; Satouchi M; Katakami N; Fujita S; Kaji R; Hata A; Urata Y; Shimada T; Uchida J; Tomii K; Morita S; Negoro S
Cancer Chemother Pharmacol; 2014 Jan; 73(1):17-23. PubMed ID: 24141372
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma.
Hirono S; Iwadate Y; Higuchi Y; Serizawa T; Nagano O; Matsutani T; Saeki N
J Neurooncol; 2015 Jun; 123(2):237-44. PubMed ID: 25911295
[TBL] [Abstract][Full Text] [Related]
25. Pemetrexed is mildly active with good tolerability in treating patients with gastric cancer.
Lan H; Lin CY; Li Y
Asian Pac J Cancer Prev; 2014; 15(17):7137-9. PubMed ID: 25227803
[TBL] [Abstract][Full Text] [Related]
26. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
[No Abstract] [Full Text] [Related]
27. Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.
Liang Y; Padda SK; Riess JW; West RB; Neal JW; Wakelee HA
Lung Cancer; 2015 Jan; 87(1):34-8. PubMed ID: 25443273
[TBL] [Abstract][Full Text] [Related]
28. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
[TBL] [Abstract][Full Text] [Related]
29. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
Langner-Lemercier S; Houillier C; Soussain C; Ghesquières H; Chinot O; Taillandier L; Soubeyran P; Lamy T; Morschhauser F; Benouaich-Amiel A; Ahle G; Moles-Moreau MP; Moluçon-Chabrot C; Bourquard P; Damaj G; Jardin F; Larrieu D; Gyan E; Gressin R; Jaccard A; Choquet S; Brion A; Casasnovas O; Colin P; Reman O; Tempescul A; Marolleau JP; Fabbro M; Naudet F; Hoang-Xuan K; Houot R
Neuro Oncol; 2016 Sep; 18(9):1297-303. PubMed ID: 26951382
[TBL] [Abstract][Full Text] [Related]
30. Results of combined-modality therapy for primary and secondary malignant lymphoma of the central nervous system (CNS).
Kawamura T; Koga S; Okamoto M; Kanno T; Iwamura H
Radiat Med; 2001; 19(3):145-9. PubMed ID: 11467381
[TBL] [Abstract][Full Text] [Related]
31. Pemetrexed is mildly active with good tolerability for treatment of patients with colorectal cancer.
Zhang HQ; Lian CH; Ping YD; Song WB; Lu QP; Xie SZ; Lin T; Cheng LZ
Asian Pac J Cancer Prev; 2014; 15(19):8391-4. PubMed ID: 25339034
[TBL] [Abstract][Full Text] [Related]
32. O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.
Adachi J; Mishima K; Wakiya K; Suzuki T; Fukuoka K; Yanagisawa T; Matsutani M; Sasaki A; Nishikawa R
J Neurooncol; 2012 Mar; 107(1):147-53. PubMed ID: 21968944
[TBL] [Abstract][Full Text] [Related]
33. Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma.
Huang XE; Tian GY; Cao J; Xu X; Lu YY; Wu XY; Liu J; Shi L; Xiang J
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6663-7. PubMed ID: 24377585
[TBL] [Abstract][Full Text] [Related]
34. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
[TBL] [Abstract][Full Text] [Related]
35. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
[TBL] [Abstract][Full Text] [Related]
36. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
Soussain C; Choquet S; Blonski M; Leclercq D; Houillier C; Rezai K; Bijou F; Houot R; Boyle E; Gressin R; Nicolas-Virelizier E; Barrie M; Moluçon-Chabrot C; Lelez ML; Clavert A; Coisy S; Leruez S; Touitou V; Cassoux N; Daniau M; Ertault de la Bretonnière M; El Yamani A; Ghesquières H; Hoang-Xuan K
Eur J Cancer; 2019 Aug; 117():121-130. PubMed ID: 31279304
[TBL] [Abstract][Full Text] [Related]
37. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.
Jahnke K; Thiel E; Martus P; Herrlinger U; Weller M; Fischer L; Korfel A;
J Neurooncol; 2006 Nov; 80(2):159-65. PubMed ID: 16699873
[TBL] [Abstract][Full Text] [Related]
38. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
[TBL] [Abstract][Full Text] [Related]
39. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.
Miller DS; Blessing JA; Drake RD; Higgins R; McMeekin DS; Puneky LV; Krasner CN
Gynecol Oncol; 2009 Dec; 115(3):443-6. PubMed ID: 19804902
[TBL] [Abstract][Full Text] [Related]
40. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.
Plotkin SR; Betensky RA; Hochberg FH; Grossman SA; Lesser GJ; Nabors LB; Chon B; Batchelor TT
Clin Cancer Res; 2004 Sep; 10(17):5643-6. PubMed ID: 15355887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]